Active, not recruitingNCT04934475MIDASUpdated Nov 7, 2024

MInimal Residual Disease Adapted Strategy

A Phase 3 interventional study of Isatuximab and ASCT in Multiple Myeloma, sponsored by Intergroupe Francophone du Myelome. Active, not recruiting at 73 sites in 3 countries. Open to participants aged 18 Years to 66 Years. Per ClinicalTrials.gov, last updated 2024-11-07.

Sponsored by Intergroupe Francophone du Myelome · Phase 3, Interventional, and Treatment

Phase: Phase 3
Study type: Interventional
Enrollment: 791
Allocation: Randomized
Ages: 18 Years to 66 Years
Sex: All

Study summary

IFM 2020-02 will enroll patients eligible for ASCT less than 66 years. All patients will receive induction based on 6 cycles (28-day) of KRD-Isatuximab (Isa-KRD), in order to achieve deep responses and high MRD negativity rates. Patients will be classified at diagnosis according to cytogenetics (standard vs high-risk cytogenetics defined by the LP score including 17p deletion, t(4;14), del(1p32), gain 1q, trisomy 21 and trisomy 5).

Read the detailed description

According to international guidelines, outside clinical trials, frontline autologous stem cell transplantation (ASCT) is the standard of care for fit patients less than 71 years of age, who are newly diagnosed with multiple myeloma.

Triplet combinations are now the backbone of induction therapy prior to ASCT. KRD (Carfilzomib, Lenalidomide, Dexamethasone) is potentially the more active regimen.

Quadruplet combinations are under evaluation. The prospective phase 3 CASSIOPEIA trial conducted by the IFM and HOVON cooperative groups investigated the outcome of transplant-eligible patients treated with VTD (Bortezomib, Thalidomide, Dexamethasone) +/- Daratumumab administered both before (induction, 4 cycles) and after (consolidation, 2 cycles) single ASCT prepared by Melphalan 200 mg/m2.5 The addition of Daratumumab to VTD during induction induced significantly higher response rates, but also higher minimal residual disease (MRD) - negativity rates. The high response rates achieved after induction (MRD negativity rates at 10-5 by 8-color flow cytometry 35% (188/543) in the VTD-Dara arm vs 23% (125/542) after 4 cycles of VTD in the intent-to-treat population), but also after consolidation and before maintenance (MRD negativity rates at 10-5 by 8-color flow cytometry 63% in the VTD-Dara arm vs 43% in the VTD in the intent-to-treat population), translated into a significant improvement in progression-free-survival (PFS) in the Daratumumab arm of the study: 18-month PFS 93% vs 85% before maintenance, HR 0.47 (0.33-0.67), p \< 0.0001. Cassiopeia is the first study showing a correlation between MRD negativity after induction (before ASCT) and PFS benefit, in the setting of quadruplet combination induction. Based on these results, VTD + daratumumab was recently approved by the FDA and EMA.

KRD has also been combined with Daratumumab in several phase 2 trials. Early results indicate that this quadruplet combination might potentially be the most effective regimen prior to ASCT in terms of response and MRD-negativity rates. Carfilzomib was administered intravenously weekly, on days 1, 8 and 15 of 28 day-cycles at the dose of 56 mg/m². Based on 70 patients, the MRD-negativity rate after four cycles of KRD-Daratumumab was 39% at a detection level of 10-5 by next generation sequencing (NGS). The weekly KRD-Daratumumab regimen was associated with low toxicity, and stem cell harvest was adequate. The rate of MRD negativity in 42 patients further improved after single ASCT, to 67% and 43% at a detection level of 10-5 and of 10-6 by NGS, respectively. Due to the short 7.9 months median follow-up time at the time of presentation, no PFS data were presented. At ASCO 2020, Weisel et al reported the results of induction based on 6 cycles of KRD plus Isatuximab, in patients with high-risk cytogenetics.8 In this interim analysis on the first 46 patients eligible for ASCT with high-risk disease, the overall response rate was 100%, including 60% MRD negativity at 10-5 by NGS after induction and before ASCT. No death on study was reported. No data are yet available regarding MRD negativity rates after ASCT or PFS. At ASH 2019, Landgren et al. reported the results of eight weekly KRD-Daratumumab cycles without ASCT in a small phase 2 study on 41 patients after a short median follow-up time of 8.6 months.

On the same intent-to-treat basis, MRD-negativity rate at a detection level of 10-5 by NGS was 61% and 65% in patients after six and eight cycles, respectively, including a very good partial response (VGPR) rate or better of 85% after 8 cycles and an overall response rate (ORR) of 100%. No death on study was seen. At the time of the report, no patient with MRD-negative disease had progressed. Despite the short follow-up time, based on the high rate of MRD-negativity and the 0% relapse rate achieved so far with this quadruplet combination, the authors of this small phase 2 series now propose to systematically delay ASCT in patients with standard-risk disease. This provocative recommendation requires validation in a phase 3 randomized trial comparing frontline versus delayed ASCT in patients with MRD-negative disease after induction.

Patients MRD positive after quadruplet induction are at higher risk of disease progression. For patients with high-risk (HR) disease, tandem ASCT has been proposed in order to improve PFS and overall survival (OS). In an integrated analysis of four phase III studies independently conducted by HOVON/GMMG, IFM, PETHEMA/GEM and GIMEMA European cooperative groups, in the era of Bortezomib-based induction regimens, double ASCT significantly improved PFS and OS in HR patients.

In the EMN02/HO95 study, in centers with a policy of double ASCT, patients were assigned to receive VMP (Bortezomib, Melphalan, Prednisone), single ASCT (ASCT-1) or two planned ASCTs (ASCT-2) to prospectively compare ASCT-1 with ASCT-2. Patients who received ASCT-2 had a prolonged PFS compared to those who received ASCT-1. Importantly, ASCT-2 overcame the adverse prognosis conferred by high-risk cytogenetics. In the same study, OS from the first randomization was significantly prolonged with ASCT-2 as compared with ASCT-1, a benefit also seen in subgroups of patients with adverse prognosis, including those with R-ISS stage II+III and high-risk cytogenetics. To date, no prospective trial has compared single vs tandem ASCT in HR patients in the era of quadruplet induction combinations.

After ASCT, a systematic maintenance is recommended by International Guidelines. Lenalidomide is approved in this setting, and proposed until progression. Other agents or combinations are under evaluation for maintenance, such as Ixazomib, Elotuzumab, Daratumumab or Isatuximab. Iberdomide is a next generation cereblon targeting agent, with antitumor and immunostimulatory activities in Lenalidomide- and Pomalidomide-resistant multiple myeloma. This oral agent, which could be the ideal agent for maintenance therapy, is currently tested after ASCT. Phase 2 and 3 randomized studies are currently investigating the combination of Lenalidomide with anti-CD38 monoclonal antibodies as maintenance therapy after autologous stem cell transplant. We assume that a fixed duration of maintenance using Iberdomide and Isatuximab will induce a high-rate of sustained MRD negativity.

Conditions studied

Multiple Myeloma

Browse trials for

Keywords

Younger patients
First line of treatment
Autograft
Isa-KRD

Who can participate

Ages eligible: 18 Years to 66 Years
Sexes eligible: All
Accepts healthy volunteers: No

Inclusion criteria

Male or female subjects, 18 years of age or older, younger than 66 years (\< 66 years)
Voluntary written informed consent must be given before performance of any study-related procedure not part of normal medical care, with the understanding that the subject may withdraw consent at any time without prejudice to future medical care.
Subject must have documented multiple myeloma satisfying the CRAB and measurable disease as defined by:
1. Monoclonal plasma cells in the bone marrow ≥ 10% or presence of a biopsy proven plasmacytoma AND any one or more of the following myeloma defining events:
  - Hypercalcemia: serum calcium > 0.25 mmol/L (> 1 mg/dL) higher than ULN or > 2.75 mmol/L (> 11 mg/dL)
  - Renal insufficiency: creatinine clearance \< 40mL/min or serum creatinine > 177 μmol/L (> 2 mg/dL)
  - Anemia: hemoglobin > 2 g/dL below the lower limit of normal or hemoglobin \< 10 g/dL
  - Bone lesions: one or more osteolytic lesions on skeletal radiography, CT or PET-CT
  - Clonal bone marrow plasma cell percentage ≥ 60%
  - Involved: uninvolved serum free light chain ratio ≥ 100
  - Superior 1 focal lesion on MRI studies
2. Measurable disease as defined by the following:
  - M-component ≥ 5g/L, and/or urine M-component ≥ 200 mg/24h and/or serum FLC ≥ 100 mg/L
Newly diagnosed subjects eligible for high dose therapy and autologous stem cell transplantation
Karnofsky performance status score ≥ 50% (eastern cooperative oncology group performance status ECOG score ≤ 2)
Subject must have pretreatment clinical laboratory values meeting the following criteria during the Screening Phase (Lab tests should be repeated if done more than 15 days before C1D1):
1. Hemoglobin ≥ 7.5 g/dL (≥ 5mmol/L). Prior red blood cell [RBC] transfusion or recombinant human erythropoietin use is permitted;
2. Absolute neutrophil count (ANC) ≥ 1.0 Giga/L (GCSF use is permitted);
3. ASAT ≤ 3 x ULN;
4. ALAT ≤ 3 x ULN;
5. Total bilirubin ≤ 3 x ULN (except in subjects with congenital bilirubinemia, such as Gilbert syndrome, direct bilirubin ≤ 1.5 x ULN);
6. Calculated creatinine clearance ≥ 40 mL/min/1.73 m²;
7. Corrected serum calcium ≤ 14 mg/dL (\< 3.5 mmol/L); or free ionized calcium ≤6.5 mg/dL (≤ 1.6 mmol/L);
8. Platelet count ≥ 50 Giga/L for subjects in whom \< 50% of bone marrow nucleated cells are plasma cells; otherwise platelet count > 50 Giga/L (transfusions are not permitted to achieve this minimum platelet count).
Women of childbearing potential must have a negative serum or urine pregnancy test within 10 to 14 days prior to therapy and repeated within 24 hours before starting study drug. They must commit to continued abstinence from heterosexual intercourse or begin 2 acceptable methods of birth control (One highly effective method and one additional effective method) used at the same time, beginning at least 4 weeks before initiation of Lenalidomide treatment and continuing for at least 30 days after the last dose of Lenalidomide, Iberdomide and 5 months after last dose of Isatuximab. Women must also agree to notify pregnancy during the study.
Men must agree to not father a child and agree to use a latex condom during therapy and during dose interruptions and for at least 90 days after the last dose of study drug including Lenalidomide and Iberdomide and 5 months after last dose of Isatuximab, even if they have had a successful vasectomy, if their partner is of childbearing potential. Patient must also refrain from donating sperm during this period.

Exclusion criteria

Exclusion Criteria:

Subjects must not have been treated previously with any systemic therapy for multiple myeloma. Prior treatment with corticosteroids or radiation therapy does not disqualify the subject (the maximum dose of corticosteroids should not exceed the equivalent of 160 mg of dexamethasone in a 2-week period). Two weeks must have elapsed since the date of the last radiotherapy treatment. Enrolment of subjects who require concurrent radiotherapy (which must be localized in its field size) should be deferred until the radiotherapy is completed and 2 weeks have elapsed since the last date of therapy.
Subject has a diagnosis of primary amyloidosis, monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or solitary plasmacytoma.
Subject has a diagnosis of Waldenström's macroglobulinemia, or other conditions in which IgM M-protein is present in the absence of a clonal plasma cell infiltration with lytic bone lesions.
Subject has had plasmapheresis within 14 days of C1D1.
Subject is exhibiting clinical signs of meningeal involvement of multiple myeloma.
Myocardial infarction within 4 months prior to enrolment according to NYHA Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities
Uncontrolled hypertension
Subjects with a history of moderate or severe persistent asthma within the past 2 years, or with uncontrolled asthma of any classification at the time of screening (Note that subjects who currently have controlled intermittent asthma or controlled mild persistent asthma are allowed in the study).
Intolerance to hydration due to pre-existing pulmonary or cardiac impairment.
Subject has plasma cell leukemia (according to WHO criterion: ≥ 20% of cells in the peripheral blood with an absolute plasma cell count of more than 2 × 109/L) or POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes).
Any clinically significant, uncontrolled medical conditions that, in the Investigator's opinion, would expose the patient to excessive risk or may interfere with compliance or interpretation of the study results.
Systemic treatment with strong inhibitors of CYP1A2 (fluvoxamine, enoxacin), strong inhibitors of CYP3A (clarithromycin, telithromycin, itraconazole, voriconazole, ketoconazole, nefazodone, posaconazole) or strong CYP3A inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. John's wort within 14 days before the first dose of study treatment.
Known intolerance to steroid therapy, mannitol, pregelatinized starch, odium stearyl fumarate, histidine (as base and hydrochloride salt), arginine hydrochloride, poloxamer 188, sucrose or any of the other components of study intervention that are not amenable to premedication with steroids and H2 blockers or would prohibit further treatment with these agents.
History of allergy to any of the study medications, their analogues, or excipients in the various formulations
Subject has had major surgery within 2 weeks before study inclusion (informed consent signature) or will not have fully recovered from surgery, or has surgery planned during the time the subject is expected to participate in the study. Kyphoplasty or Vertebroplasty are not considered major surgery.
Clinically relevant active infection or serious co-morbid medical conditions
Prior malignancy except adequately treated basal cell or squamous cell skin cancer, in situ cervical, breast or prostate cancer free of disease since 5 years.
Female subject who is pregnant or breast-feeding
Serious medical or psychiatric illness likely to interfere with participation in study
Uncontrolled diabetes mellitus
Known HIV infection; Known active hepatitis A, B or C viral infection
Uncontrolled or active HBV infection: Patients with positive HBsAg and/or HBV DNA
Of note:
- Patient can be eligible if anti-HBc IgG positive (with or without positive anti-HBs) but HBsAg and HBV DNA are negative.
- If anti-HBV therapy in relation with prior infection was started before initiation of IMP, the anti-HBV therapy and monitoring should continue throughout the study treatment period.
- Patients with negative HBsAg and positive HBV DNA observed during screening period will be evaluated by a specialist for start of anti-viral treatment: study treatment could be proposed if HBV DNA becomes negative and all the other study criteria are still met.
Active HCV infection: positive HCV RNA and negative anti-HCV
Of note:
- Patients with antiviral therapy for HCV started before initiation of IMP and positive HCV antibodies are eligible. The antiviral therapy for HCV should continue throughout the treatment period until seroconversion.
- Patients with positive anti-HCV and undetectable HCV RNA without antiviral therapy for HCV are eligible.
Active systemic infection and severe infections requiring treatment with a parenteral administration of antibiotics.
Incidence of gastrointestinal disease that may significantly alter the absorption of oral drugs
Subjects unable or unwilling to undergo antithrombotic prophylactic treatment
Person under guardianship, trusteeship or deprived of freedom by a judicial or administrative decision

Study design

Phase: Phase 3
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Factorial assignment
Masking: None (open label)
Enrollment: 791 participants (actual)

Study arms

Experimental
MRD Standard-risk patients (post induction MRD <10-5, MRD SR) (1:1 Randomization) : Arm A
Arm A: consolidation with 6 additional cycles of Isa-KRD (cycles 7 to 12; 28-day cycle; Isa-KRD = Isatuximab Carfilzomib Lenalidomide Dexamethasone): * Isatuximab: 10 mg/kg I.V. on days 1 and 15 (cycles 7 to 12) * Carfilzomib: 56 mg/m2 I.V on days 1, 8 and 15 (cycles 7 to 12) * Lenalidomide: 25 mg per day orally from days 1 to 21 * Dexamethasone: 40 mg orally on day 1, 8, 15, 22
Drug: Isatuximab
Experimental
MRD Standard-risk patients (post induction MRD <10-5, MRD SR) (1:1 Randomization): Arm B
Arm B: consolidation with ASCT followed by 2 cycles of Isa-KRD (cycles 7 and 8; Isa-KRD = Isatuximab Carfilzomib Lenalidomide Dexamethasone; 28-day cycle) Melphalan 200 mg/m2 followed by autologous stem cell transplantation (please refer to section 6.3.2) * Isatuximab: 10 mg/kg I.V. on days 1 and 15 (cycles 7 to 8) * Carfilzomib: 56 mg/m2 I.V on days on days 1, 8 and 15 (cycles 7 to 8) * Lenalidomide: 25 mg per day orally from days 1 to 21 * Dexamethasone: 40 mg orally on days 1, 8, 15, 22 (cycles 7 to 8)
Drug: Isatuximab · Procedure: ASCT
Experimental
MRD High-risk patients (post induction MRD >10-5, MRD HR) (1:1 Randomization): Arm C
Arm C: ASCT followed by 2 cycles of Isa-KRD (cycles 7 and 8; Isa-KRD = Isatuximab Carfilzomib Lenalidomide Dexamethasone; 28-day cycle) Melphalan 200 mg/m2 followed by autologous stem cell transplantation. * Isatuximab: 10 mg/kg I.V. on days 1 and 15 (cycles 7 to 8) * Carfilzomib: 56 mg/m2 I.V on days on days 1, 8 and 15 (cycle 7 to 8) * Lenalidomide: 25 mg per day orally from day 1 to day 21 * Dexamethasone: 40 mg orally on days 1, 8, 15, 22 (cycle 7 to 8)
Drug: Isatuximab · Procedure: ASCT
Experimental
MRD High-risk patients (post induction MRD >10-5, MRD HR) (1:1 Randomization): Arm D
Tandem ASCT Melphalan 200 mg/m2 followed by autologous stem cell transplantation.
Procedure: ASCT

Interventions

DrugIsatuximab
Treatment with Isa-KRD during induction and consolidation , with Lenalidomide (Revlimid) or Iberdomide + Isatuximab during maintenance phase
Also known as: Carfilzomib, Revlimid, Dexamethasone
ProcedureASCT
ASCT for ams B, C and D during consolidation

What researchers measure

Primary outcomes

Negative MRD rate
For both parts of the trial (A vs B and C vs D), the primary comparison of the 2 strategies will be made with respect to negative MRD rate (10-6 NGS) before maintenance using the chi square test in the ITT population. The observed MRD negative rate will be provided along with its 2-sided 95% Confidence interval (CI). Treatment effect will be described by an Odds Ratio, along with its 2-sided 95% confidence interval, by fitting a logistic regression model adjusted on stratification variables (with high risk cytogenetics and MRD negative rate (10-5 NGS) after induction as fixed effects and center as random effects for A vs B comparison, and high risk cytogenetics as fixed effects and center as random effects for C vs D comparison). In case of missing MRD, data will be imputed as positive in all arms. Sensitivity analyses will be performed using best-worst and worst-best case to check for robustness of the results.
Time frame: Time Frame: change from post induction baseline MRD at end of consolidation phase (6 months)
Negative MRD rate
For both parts of the trial (A vs B and C vs D), the primary comparison of the 2 strategies will be made with respect to negative MRD rate (10-6 NGS) before maintenance using the chi square test in the ITT population. The observed MRD negative rate will be provided along with its 2-sided 95% Confidence interval (CI). Treatment effect will be described by an Odds Ratio, along with its 2-sided 95% confidence interval, by fitting a logistic regression model adjusted on stratification variables (with high risk cytogenetics and MRD negative rate (10-5 NGS) after induction as fixed effects and center as random effects for A vs B comparison, and high risk cytogenetics as fixed effects and center as random effects for C vs D comparison). In case of missing MRD, data will be imputed as positive in all arms. Sensitivity analyses will be performed using best-worst and worst-best case to check for robustness of the results.
Time frame: change from post induction baseline MRD at 1 years
Negative MRD rate
For both parts of the trial (A vs B and C vs D), the primary comparison of the 2 strategies will be made with respect to negative MRD rate (10-6 NGS) before maintenance using the chi square test in the ITT population. The observed MRD negative rate will be provided along with its 2-sided 95% Confidence interval (CI). Treatment effect will be described by an Odds Ratio, along with its 2-sided 95% confidence interval, by fitting a logistic regression model adjusted on stratification variables (with high risk cytogenetics and MRD negative rate (10-5 NGS) after induction as fixed effects and center as random effects for A vs B comparison, and high risk cytogenetics as fixed effects and center as random effects for C vs D comparison). In case of missing MRD, data will be imputed as positive in all arms. Sensitivity analyses will be performed using best-worst and worst-best case to check for robustness of the results.
Time frame: change from post induction baseline MRD at 2 years
Negative MRD rate
For both parts of the trial (A vs B and C vs D), the primary comparison of the 2 strategies will be made with respect to negative MRD rate (10-6 NGS) before maintenance using the chi square test in the ITT population. The observed MRD negative rate will be provided along with its 2-sided 95% Confidence interval (CI). Treatment effect will be described by an Odds Ratio, along with its 2-sided 95% confidence interval, by fitting a logistic regression model adjusted on stratification variables (with high risk cytogenetics and MRD negative rate (10-5 NGS) after induction as fixed effects and center as random effects for A vs B comparison, and high risk cytogenetics as fixed effects and center as random effects for C vs D comparison). In case of missing MRD, data will be imputed as positive in all arms. Sensitivity analyses will be performed using best-worst and worst-best case to check for robustness of the results.
Time frame: change from post induction baseline MRD at 3 years

Secondary outcomes

Sustained MRD rate
Sustained MRD rate at after consolidation phase ( 6 months) than year 1, 2, 3 post consolidation phase will be analyzed similarly to the primary endpoint
Time frame: change from post induction baseline MRD at end of consolidation phase (6 months)
Sustained MRD rate
Sustained MRD rate at after consolidation phase ( 6 months) than year 1, 2, 3 post consolidation phase will be analyzed similarly to the primary endpoint
Time frame: change from post induction baseline MRD at 1 years
Sustained MRD rate
Sustained MRD rate at after consolidation phase ( 6 months) than year 1, 2, 3 post consolidation phase will be analyzed similarly to the primary endpoint
Time frame: change from post induction baseline MRD at 2 years
Sustained MRD rate
Sustained MRD rate at after consolidation phase ( 6 months) than year 1, 2, 3 post consolidation phase will be analyzed similarly to the primary endpoint
Time frame: change from post induction baseline MRD at 3 years
Overall Survival (OS)
For Overall Survival (OS), the distribution of OS since randomization will be estimated using Kaplan Meier method. The comparison of the 2 arms will be made by log-rank test. Treatment effect will be described by Hazard Ratio and its 2-sided 95% confidence intervals will be estimated using a Cox regression model adjusted on stratification variables (with high risk cytogenetics and MRD negative rate (10-5 NGS) after induction as fixed effects and center as random effects for A vs B comparison, and high risk cytogenetics as fixed effects and center as random effects for C vs D comparison).
Time frame: through study completion, an average of 8 year
Progression Free Survival (PFS)
Progression Free Survival, defined as time from randomization to either progression or death will be analyzed similarly to OS
Time frame: through study completion, an average of 8 year
Safety analyses
rate of adverse events that occured during treatment period
Time frame: until 30 days post last dose of protocol treatment

Study locations

73 sites

Institut Jules Bordet
Bruxelles, 1070, Belgium
Cliniques Universitaires Saint-Luc
Bruxelles, 1200, Belgium
Grand Hôpital de Charleroi - Site de Notre-Dame
Charleroi, B 6000, Belgium
Hôpital Jolimont
Haine-Saint-Paul, 7100, Belgium
CHU de Liège
Liège, 4000, Belgium
CHU UCL Namur (Site Godinne)
Yvoir, B 5530, Belgium
CHU Amiens Sud
AMIENS Cedex 1, France
CHRU-Hôpital du Bocage
ANGERS Cedex 1, France
Centre Hospitalier d'Argenteuil Victor Dupouy
Argenteuil, France
Centre Hospitalier H.Duffaut
AVIGNON Cedex 9, France
Centre hospitalier de la Côte Basque
Bayonne, France
Hôpital Jean Minjoz
BESANCON Cedex, France
Centre Hospitalier Simone Veil
Blois, France
Hôpital Avicenne
BOBIGNY Cedex, France
CHRU Hôpital Haut Lévêque - Centre François Magendie
Bordeaux Pessac, France
Polyclinique Bordeaux Nord Acquitaine
Bordeaux, France
Hôpital de Fleyriat
BOURG EN BRESSE Cedex, France
CHRU Brest - Hôpital A. Morvan
BREST Cedex, France
CHU Caen - Côte de Nacre
CAEN Cedex, France
CH René Dubos
Cergy-pontoise, France
Centre Hospitalier William Morey
Chalon-sur-Saône, 71100, France
CH Chambéry
Chambery, France
Hôpital d'Instruction des Armées Percy
CLAMART Cedex, France
Chu Estaing
Clermont-Ferrand, France
Centre Hospitalier Sud Francilien
CORBEIL-ESSONNES Cedex, France
CHU Henri Mondor
Creteil, France
CHU Dijon Hôpital d'enfants
Dijon, France
Centre Hospitalier Général
Dunkerque, France
CHRU Hôpital A. Michallon
GRENOBLE Cedex 9, France
CHD Vendée
LA ROCHE SUR YON Cedex 9, France
CHV André Mignot - Université de Versailles
Le Chesnay, France
CH de Chartres - Hôpital Louis Pasteur
Le Coudray, France
Hôpital Jacques Monod
Le Havre, France
Centre Hospitalier
LE MANS Cedex, France
CHRU Hôpital Claude Huriez
LILLE Cedex, France
GH de l'Institut Catholique Saint Vincent
Lille, France
Centre Hospitalier Universitaire (CHU) de Limoges
Limoges, France
Hôpital du Scorff
Lorient, France
Centre Léon Bérard
Lyon, France
Institut Paoli Calmettes
MARSEILLE Cedex, France
CH Meaux
Meaux, France
Hôpital de Mercy (CHR Metz-Thionville)
METZ Cedex 1, France
Hopital Saint Eloi - CHU Montpellier
MONTPELLIER Cedex, France
Hôpital E. Muller
Mulhouse, France
CHRU Hôtel Dieu
Nantes Cedex 1, France
Clinique de l'Archet
NICE Cedex 3, France
CHU Carémeau
NIMES Cedex 9, France
CH La Source
Orleans Cedex 2, France
Hôpital Saint Louis
PARIS Cedex 10, France
CHU Hôpital Saint Antoine
PARIS Cedex 12, France
Hôpital Cochin
Paris, France
Hôpital Necker
Paris, France
Institut Curie
Paris, France
La Pitié- Salpetrière
Paris, France
Centre Hospitalier de Perigueux
Perigueux, France
CH Saint Jean
Perpignan, France
Hospices Civils de Lyon - Hôpital Lyon Sud
Pierre-Bénite Lyon, France
CHU Poitiers - Pôle régional de Cancérologie
Poitiers, France
Ch Annecy Genevois
PRINGY Cedex, France
Centre Hospitalier Intercommunal de Cornouaille
Quimper, France
Hôpital Robert Debré
REIMS Cedex, France
CHRU Hôpital de Pontchaillou
RENNES Cedex 9, France
Centre Henri Becquerel
ROUEN Cedex 1, France
Institut de Cancérologie Lucien Neuwirth
Saint Priest-en-jarez, France
Centre Hospitalier Yves Le Foll
Saint-brieuc, France
Centre Hospitalier de Saint-Quentin
Saint-Quentin, France
Hôpitaux Universitaires de Strasbourg - Hôpital de Hautepierre
Strasbourg, France
Pôle IUCT Oncopole CHU
TOULOUSE Cedex 9, France
CHRU Hôpital Bretonneau
TOURS Cedex, France
CHRU Hôpitaux de Brabois
VANDOEUVRE LES NANCY Cedex, France
CHBA
VANNES Cedex, France
Gustave Roussy
Villejuif, France
CHU de La Réunion site Sud
Saint-Pierre, Réunion

References and documents

Publications

Mohan M, Gundarlapalli S, Szabo A, Yarlagadda N, Kakadia S, Konda M, Jillella A, Fnu A, Ogunsesan Y, Yarlagadda L, Thalambedu N, Munawar H, Graziutti M, Al Hadidi S, Alapat D, Thanendrarajan S, Zangari M, van Rhee F, Schinke C. Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma. Am J Hematol. 2022 Jun 1;97(6):E195-E198. doi: 10.1002/ajh.26530. Epub 2022 Mar 21. No abstract available. PubMed 35285981 ↗

Registry details

Key details

Study ID: NCT04934475
Lead sponsor: Intergroupe Francophone du Myelome
Collaborators: Amgen, Sanofi, Bristol-Myers Squibb
Responsible party: Sponsor
First posted: Jun 22, 2021
Start date: Dec 8, 2021
Primary completion: Sep 30, 2024
Completion: Sep 30, 2028 (estimated)
Last update: Nov 7, 2024

Study contacts

Philippe Moreau, Professor

principal investigator · Nantes University Hospital

Oversight

Data monitoring committee: Yes
FDA-regulated drug: Yes
FDA-regulated device: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Multiple Myeloma→

Other studies from this sponsor

Intergroupe Francophone du Myelome

Start the discussion